Literature DB >> 27463633

DRESS syndrome in ophthalmic patients.

Jacqueline Martins de Sousa1, Heloisa Nascimento1, Rubens Belfort1.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and potentially fatal adverse drug reaction associated with skin rash, fever, eosinophilia, and multiple organ injury. A number of pharmacological agents are known to cause DRESS syndrome such as allopurinol, anticonvulsants, vancomycin, trimethoprime-sulfamethoxazole, and pyrimethamine-sulfadiazine. Here, we describe two patients who developed DRESS syndrome during ocular treatment. The first case was being treated for late postoperative endophthalmitis with topical antibiotics, intravenous cephalothin, meropenem, and intravitreal injection of vancomycin and ceftazidime before symptoms developed. We were unable to identify the causal drug owing to the large number of medications concurrently administered. The second case presented with DRESS syndrome symptoms during ocular toxoplasmosis treatment. In this case, a clearer association with pyrimethamine-sulfadiazine was observed. As a result of the regular prescription of pharmacological agents associated with DRESS syndrome, ophthalmologists should be aware of the potentially serious complications of DRESS syndrome.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27463633     DOI: 10.5935/0004-2749.20160055

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  2 in total

1.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient with Bipolar Disorder: A Case Report.

Authors:  Snehil Gupta; Raman Deep; Sudhir Kumar Khandelwal; Binod K Khaitan
Journal:  Indian J Psychol Med       Date:  2021-02-22

Review 2.  Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review.

Authors:  Shiva Sharifzadeh; Amir Hooshang Mohammadpour; Ashraf Tavanaee; Sepideh Elyasi
Journal:  Eur J Clin Pharmacol       Date:  2020-10-06       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.